A Phase 2, Open-label, Safety, Tolerability, and Efficacy Trial of a Botanical Drug at One Dose Level for the Treatment of External Condylomata Acuminata (Genital Warts) in Adult Immunocompetent Subjects
Latest Information Update: 05 May 2021
Price :
$35 *
At a glance
- Drugs Santalum album (Primary)
- Indications Condylomata acuminata
- Focus Adverse reactions
- Sponsors Santalis Healthcare Corporation
- 05 May 2021 Status changed from recruiting to discontinued as sponsor terminated study due to financial constraints.
- 15 Jan 2019 Planned End Date changed from 1 Mar 2018 to 1 Dec 2019.
- 15 Jan 2019 Planned primary completion date changed from 1 Jan 2018 to 1 Aug 2019.